Antimicrobial innovation by Big Pharma has slowed to a crawl while an epidemic of antimicrobial-resistant infections surges, threatening the public health. The overarching goal ofthe Wisconsin Antimicrobial Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial resistance crisis. Based upon our preliminary data, we hypothesize that natural product exploration of symbiotic environments using complementary cutting-edge approaches will provide a new paradigm for discovery of novel antimicrobials targeting drug resistant infections. The Center proposes innovative conceptual and technical advances to overcome critical bottlenecks identified in traditional antimicrobial drug discovery platforms. The success of this endeavor is dependent upon the ability to predict antimicrobial effectiveness ofthe symbiotic natural products in humans. The In vivo Core will assess the in vivo microbiologic effectiveness, mammalian safety, pharmacokinetics and pharmacodynamics of promising novel natural product scaffolds from each Project (1, 2, 3) in the Center. The Core uses clinically relevant murine infection models with each ofthe target, drug-resistant pathogens - fungal and gram-positive and negative bacteria. The results from these Core activities will predict which compounds with promising in vitro activity against drug-resistant pathogens are likely to progress to a clinically useful antimicrobial drug. The core services will also provide data that answer the question: which of the novel discovery approaches employed by our three CETR projects best delivers lead antimicrobial compounds. Elucidation of optimal discovery strategies will yield a transformative and sustained impact on the development of new drugs.
There are no effective therapies for the emerging resistant pathogens that are becoming an increasing threat to the public health. The goals of the Center are to provide new, broad spectrum antimicrobial agents through a collaborative focus on high value natural product leads produced by under-explored sources of biological diversity.
|Adnani, Navid; Rajski, Scott R; Bugni, Tim S (2017) Symbiosis-inspired approaches to antibiotic discovery. Nat Prod Rep 34:784-814|
|Lawry, Stephanie M; Tebbets, Brad; Kean, Iain et al. (2017) Fludioxonil Induces Drk1, a Fungal Group III Hybrid Histidine Kinase, To Dephosphorylate Its Downstream Target, Ypd1. Antimicrob Agents Chemother 61:|
|Ramadhar, Timothy R; Zheng, Shao-Liang; Chen, Yu-Sheng et al. (2017) The Crystalline Sponge Method: A Solvent-Based Strategy to Facilitate Noncovalent Ordered Trapping of Solid and Liquid Organic Compounds. CrystEngComm 19:4528-4534|
|Mevers, Emily; Chouvenc, Thomas; Su, Nan-Yao et al. (2017) Chemical Interaction among Termite-Associated Microbes. J Chem Ecol 43:1078-1085|
|Zhang, Fan; Barns, Kenneth; Hoffmann, F Michael et al. (2017) Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris. J Nat Prod 80:2551-2555|
|Mevers, Emily; Saurí, Josep; Liu, Yizhou et al. (2016) Homodimericin A: A Complex Hexacyclic Fungal Metabolite. J Am Chem Soc 138:12324-7|
|Lewin, Gina R; Carlos, Camila; Chevrette, Marc G et al. (2016) Evolution and Ecology of Actinobacteria and Their Bioenergy Applications. Annu Rev Microbiol 70:235-54|
|Ruzzini, Antonio C; Clardy, Jon (2016) Gene Flow and Molecular Innovation in Bacteria. Curr Biol 26:R859-R864|
|Zhang, Yan; Adnani, Navid; Braun, Doug R et al. (2016) Micromonohalimanes A and B: Antibacterial Halimane-Type Diterpenoids from a Marine Micromonospora Species. J Nat Prod 79:2968-2972|
|Arango, R A; Carlson, C M; Currie, C R et al. (2016) Antimicrobial Activity of Actinobacteria Isolated From the Guts of Subterranean Termites. Environ Entomol 45:1415-1423|
Showing the most recent 10 out of 17 publications